Skip to main content
. 2016 May 23;126(7):2495–2508. doi: 10.1172/JCI83361

Figure 5. miR-140-5p attenuates experimental PAH in the Sugen hypoxic rat model of PAH.

Figure 5

(A) Experimental time line. (B) PAAT at weeks 0, 8, and 11. (C) RVSP at week 11. (D) RVH at 11 weeks. (E) qPCR showing whole lung miR-140-5p levels at 11 weeks. (F) Representative photomicrographs of lung sections from SCR and miR-140-5p mimic–treated animals at 11 weeks. Sections stained with Alcian blue EVG, α-SMA, and PCNA (photomicrographs representative of n = 5–7 per group). Original magnification, ×200. Scale bars: 50 μm. (G and H) Pulmonary vascular remodeling by percentage of muscularized vessels (G) and medial wall thickness as a ratio of total vessel size (media/CSA) (H). (B–H: n = 5–7 per group, *P < 0.05, **P < 0.01, 2-tailed Mann-Whitney U test, mean ± SEM).